GTx and Tessera form prostate cancer test deal:
This article was originally published in Clinica
In what could lead to a marriage of therapy and diagnostics for prostate cancer, biopharmaceutical firm GTx has linked up with Tessera to develop a blood or urine test for premalignant prostate lesions that can become cancerous. Under the agreement, Memphis, Tennessee-based GTx will provide clinical samples from its completed phase IIb clinical trial of its Acapodene (toremifene citrate) agent for reducing the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN). Tessera's early prostate cancer antigen, ProstaMark, will be used to identify patients with PIN lesions and/or early-stage prostate cancer.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.